



## Provider Alert

### 340B Drug Pricing Program Update

Effective Jan. 1, 2018, we are reimbursing separately payable drugs and biologicals purchased through the 340B program at an adjusted amount of ASP minus 22.5 percent to eligible care providers who are paid under the OPPS. This aligns with Centers for Medicare and Medicaid Services (CMS) payment policy for these drugs and biologicals. Changes that affect how we reimburse for payable drugs and biological agents purchased through the 340B Drug Pricing Program were communicated in a June 2018 letter to care providers as well as an article that appeared in the [July 2018 edition of the Network Bulletin](#).

On Sept. 1, 2018, we announced on [UHCprovider.com](http://UHCprovider.com) that due to care provider concerns we would place a temporary hold on our initial implementation of prospective edits and retrospective recoveries to further review our process for payment accuracy on drugs purchased through the 340B program and gather additional feedback.

Effective Nov. 12, 2018 we will remove the temporary hold and implement a revised approach for retrospectively pursuing targeted recoupment efforts based on feedback gathered from care providers. The hold will remain in place for all prospective edits. Please visit [Additional Drug and Pharmacy Resources](#) for answers to frequently asked questions about our revised approach.

#### We're Here to Help

If you have additional questions about 340B Drug Pricing Program, please contact Provider Services at 877-842-3210.